Patents
Genes with ES cell-specific expression
Patent Number: 7,250,255Genes associated with pluripotency, or "stemness" are very important not only from a scientific research perspective, but also from the perspective of clinically developing stem cell therapeutics. Specifically, during clinical development of any biological, it is important to possess numerous quality control assays. The current patent covers a novel gene whose expression seems to be...
Inventors: Yamanaka; Shinya (Osaka-shi 543-0033, JP)
Assignee: Yamanaka Shinya (Osaka, JP); Dainippon Sumitomo Pharma Co., Ltd. (Osaka, JP)
Date of First Priority Issue: Thursday May 31st, 2001
Antibody recognizing a small subset of human hematopoietic cells
Patent Number: 7,247,718This patent covers an antibody that binds CD34 cells called MG-1. This is a useful patent for people trying to circumvent Baxter's CD34 patent or Miltenyi's CD133.
Inventors: Lawman; Michael J. P. (Chipley, FL), Lawman; Patricia (Chipley, FL)
Assignee: Morphogenesis, Inc. (Oldsmar, FL)
Date of First Priority Issue: Wednesday November 13th, 1996
Method for producing dendritic cells
Patent Number: 7,247,480Dendritic cells are one of the most important cells of the immune system, having the unique ability to stimulate naive T cells. Additionally, under specific conditions, dendritic cells can give rise to T regulatory cells and dampen immune responses. The current patent teaches ways of generating dendritic cells from embryonic stem cells by culturing embryoid bodies with IL-3 and/or GM-CSF.
Inventors: Waldmann; Herman (Oxford, GB), Fairchild; Paul J. (Oxford, GB), Gardner; Richard (Oxford, GB), Brook; Frances (Oxford, GB)
Assignee: ISIS Innovation Limited (Oxford, GB)
Date of First Priority Issue: Thursday November 5th, 1998
Pigment epithelial cell of the eye, its production and use in therapy of an eye or CNS disease
Patent Number: 7,247,479This patent covers a method for producing a pigment epithelial cell of the eye through in vivo transfection of therapeutic genes such as neurotrophic factors, antiangiogenic factors, antioxidative factors, lysosomal factors, and/or vasodilating factors.
Inventors: Kochanek; Stefan (Koln, DE), Schraermeyer; Ulrich (Neuss, DE), Thumann; Gabriele (Koln, DE)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday February 21st, 2001
Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
Patent Number: 7,247,477The patent covers generation of angiogenic cells from embryonic stem cells using a novel method. Specifically the patent covers a way to generate such angiogenic cells by: 1) culturing individual ES cells in an unaggregated state under conditions that induce differentiation into vasculagenic progenitors (the claim is not limited by what those conditions are!) 2) isolating cells smaller...
Inventors: Itskovitz-Eldor; Joseph (Haifa, IL), Gerecht-Nir; Sharon (Haifa, IL)
Assignee: Technion Research & Development Foundation Ltd. (Haifa, IL)
Date of First Priority Issue: Tuesday April 16th, 2002
Treatment of brain damage
Patent Number: 7,247,298This patent covers the use of neuroepithelial stem cells for treating brain damage. The claims specifically encompass conditionally immortalized cells and their administration into areas contra-lateral to the region where brain damage as occured. The point the the cells have activity when administered in the contralateral region is very interesting. The patent specifically defines...
Inventors: Hodges; Helen (London, GB)
Assignee: ReNeuron Limited (GB)
Date of First Priority Issue: Monday March 29th, 1999
Recombinant human albumin fusion proteins with long-lasting biological effects
Patent Number: 7,244,833This patent covers novel vectors for generating fusion proteins comprising one or more regions of the human albumin protein. The patent covers specific nucleotide sequences and most notable albumin-G-CSF fusions that have 5 times longer self life as compared to unmodified G-CSF and at least 3 fold longer half life in plasma. This patent is useful for entities seeking the generate recombinant...
Inventors: Yu; Zailin (Baltimore, MD), Fu; Yan (Baltimore, MD)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Sunday July 1st, 2001
Valve treatment catheter and methods
Patent Number: 7,244,242This patent covers a deliver catheter for treatment of various heart conditions, especially valvular degeneration. The catheter is designed in such a method that stem cell administration can be performed with it.
Inventors: Freyman; Toby (Watertown, MA)
Assignee: Boston Scientific Scimed, Inc. (Maple Grove, MN)
Date of First Priority Issue: Monday December 30th, 2002
Regulation of cytotrophoblast cell differentiation and cell migration
Patent Number: 7,244,707Although this patent describes modulation of stem cell migration in the specification, the claims are restricted to the regulation of placental size. Specifically, the patent claims the use of IGF-2 to augment "placental growth, placental function, placental development and placental differentiation" in a mammal. The inventors appear to be the first to discover that IGF-2 outcompetes latent...
Inventors: Roberts; Claire (Adelaide, AU), Owens; Phillip (Cheongju, KR)
Assignee: Adelaide Research & Innovation Pty Ltd (South Australia, AU)
Date of First Priority Issue: Friday August 30th, 2002
Thrombopoietin mimetics
Patent Number: 7,241,783Thrombopenia, induced by chemotherapy, malignancy or radiotherapy is a substantial clinical problem. Protein therapeutics such as G-CSF have been developed and clinically implimented to deal with leukopenia. Similarly, thrombopoietin is under development as a treatment for thrombopenia. Unfortunately, various characteristics of the whole protein make it not an optimal treatment. The current patent...
Inventors: Duffy; Kevin J. (Collegeville, PA), Luengo; Juan I. (Collegeville, PA), Miller; Stephen G. (San Diego, CA), Jenkins; Julian (Collegeville, PA), Price; Alan T. (Collegeville, PA), Shaw; Antony N. (Collegeville, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA); Ligand Pharmaceutical (San Diego, CA)
Date of First Priority Issue: Tuesday December 19th, 2000